Evidence map›Paper›PMID 42535053›Full record

ReviewFrontiers in pharmacology2026

A comprehensive review on bacterial endophytic secondary metabolites: a road map from crude extract to lead molecule production.

Reshma Biju, W Jabez Osborne

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Reshma BijuSchool of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
W Jabez OsborneSchool of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endophytes are microorganisms that are concealed within the intracellular spaces of the plants in diverse ecological niches across varied habitats, are a prolific source of bioactive metabolites capable of inhibiting human pathogens responsible for mild to severe infections. The rising threat of antimicrobial resistance largely due to the indiscriminate use of antibiotics, has prompted the World Health Organization to advocate for rigorous stewardship of existing drugs while simultaneously urging the development of novel therapeutic alternatives. Several studies have reported emphasizing the application of multiple metabolites from endophytes however, exploring the mechanisms involved in the inhibition by a single effective metabolite which could help in unwinding the complexity during lead molecule synthesis. This review aims to present a comprehensive and strategic roadmap integrating upstream processes encompassing isolation, screening, and fermentation, with downstream methodologies for metabolite extraction, purification and structural elucidation, along with toxicity assessments for effective pharmaceutical applications. Furthermore, the discussion also considers the integration of predictive AI-ML models in accelerating the drug developmental pipeline for circumventing the traditional discovery bottlenecks highlighting the relevance to industrial translation and underlines the potential of endophyte-derived metabolites to target pathogenicity islands, offering a paradigm shift from bacterial eradication to anti-virulence strategies along with a focus on errors and limitations of endophytic research.

Indexed as

downstream processhigh-throughput technologiespathogenicity islandssingle metabolitetoxicity assessmentupstream process

Identifiers

PMID42535053
PMCPMC13422558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.